anonymous
Guest
anonymous
Guest
Novartis is the company that has shown interest. Not Alcon. It was actually a question from the audiance at their sales meeting. No answer was given, but many felt the non answer and the way it was not answered meant it was a strong possibility. They have been VOCAL about wanting to expand into dry eye-it is even on their web site. Will they make a deal? Who knows. If they do, do they need an entire salesforce for a drug that has been launched and on the market for 3 years? If you were tje CEO, would you buy a sales force or migrate the product to current reps? Think about what their reps have (or-dont have) in their bag now. In case you dont know- nothing much and nothing new.